Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three extra minutes on an MRI could catch a deadly side effect of cancer treatment

NCT ID NCT05125965

Diagnosis Sponsor: Centre Chirurgical Marie Lannelongue Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding just 3 minutes to a cardiac MRI can help doctors find heart inflammation (myocarditis) early in cancer patients on immunotherapy. Myocarditis is a rare but often deadly side effect of these drugs. The researchers will scan 200 patients who already need a heart MRI, to see if the extra time improves detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
additional time for the MRI
What this could lead to
If successful, this could make cardiac MRI a standard early test for heart inflammation caused by immunotherapy, improving survival.
What could go wrong
This is an observational study, not a treatment trial. The added MRI time may not improve detection enough to change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing immunotherapy with an indication for cardiac MRI for suspected myocarditis or other cardiovascular complications * Patient over 18 years of age * Patient affiliated to a health insurance plan * Patient who has given free, informed and oral consent Exclusion Criteria: * Contraindication to immunotherapy * Pregnant or breastfeeding patient (if applicable) * Contraindication to cardiac MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocarditis

Contacts and locations

Locations

  • Centre Chirurgical Marie Lannelongue

    Le Plessis-Robinson, 92350, France

  • Hopital Paris Saint Joseph

    Paris, 75014, France

  • Hôpital Europeen Marseille

    Marseille, 13003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.